Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
about
Carcinoma ex pleomorphic adenoma, with particular emphasis on early lesionsCarcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular dataCarcinoma ex pleomorphic adenoma: case report and options for systemic therapyHuman Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature.Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.Trastuzumab for Her2/neu-positive metastatic salivary gland carcinoma: Case report and review of the literature.A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases.Outcomes and prognostic factors for surgery followed by modern radiation therapy in parotid gland carcinomas.Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Cytogenetic and immunohistochemical biomarker profiling of therapy-relevant factors in salivary gland carcinomas.
P2860
Q24598710-67F916E3-6608-4C83-AFBD-5F31B347FB95Q24610239-F01242AE-ED90-4213-BB50-372C198FB920Q33840219-083D4A40-68E0-4431-9B74-0315B1CCC112Q35230643-7E8DE51C-D357-428E-81AA-15732758F5FAQ35333614-E1F37848-A4FA-48F4-9079-01CEA9A89298Q37484495-B691FDF9-8A72-4723-AC9C-D01BBCC86137Q38119240-7A3E930B-E136-4405-AC5F-A2E56578D45CQ38841254-C5F157BD-728F-47C2-BD5F-EF3C0B2A41A8Q40693954-5D8E266F-EF7E-42CD-BF8E-191C4FD4BFD9Q41906973-78BC2486-0633-4D98-A8B0-D22594BB2720Q42936492-F5D48402-5039-41DD-99DB-BFAA6421EF0EQ45996599-4704C4AB-4F15-42F3-8A27-F3FCA4069811Q48123633-1F4CE473-F058-489C-8BF5-9DC860456981Q50675747-2C47C007-52AA-4A35-85F9-60FA04BB17C1
P2860
Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sustained response of carcinom ...... trastuzumab and capecitabine.
@ast
Sustained response of carcinom ...... trastuzumab and capecitabine.
@en
type
label
Sustained response of carcinom ...... trastuzumab and capecitabine.
@ast
Sustained response of carcinom ...... trastuzumab and capecitabine.
@en
prefLabel
Sustained response of carcinom ...... trastuzumab and capecitabine.
@ast
Sustained response of carcinom ...... trastuzumab and capecitabine.
@en
P2860
P356
P1433
P1476
Sustained response of carcinom ...... h trastuzumab and capecitabine
@en
P2093
Elad Sharon
Ronan J Kelly
P2860
P2888
P356
10.1186/1758-3284-2-12
P50
P577
2010-05-26T00:00:00Z
P5875
P6179
1038165661